<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04633850</url>
  </required_header>
  <id_info>
    <org_study_id>Smerter efter VATS</org_study_id>
    <nct_id>NCT04633850</nct_id>
  </id_info>
  <brief_title>Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients</brief_title>
  <official_title>Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients: A Before and After Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jannie Bisgaard Stæhr</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aalborg University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the effect of intercostal blockade with and without adjuvants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Video-assisted thoracoscopic surgery (VATS) is a minimally invasive routine procedure. It's&#xD;
      less invasive than thoracotomy but postoperative pain is still a problem.&#xD;
&#xD;
      At Aalborg University Hospital, intercostal blockades with bupivacaine is used as standard&#xD;
      pain treatment for patients undergoing VATS. Adding adjuvants to the blockades may prolong&#xD;
      the effect.&#xD;
&#xD;
      The aim of this study is to investigate if intercostal nerve blockade with adjuvants&#xD;
      (intravenous (IV) dexamethasone) will result in better pain management.&#xD;
&#xD;
      The primary plan was to evaluate the effect of adding IV dexamethasone and perineural&#xD;
      adrenaline, but due to adverse effects, adrenaline was first reduced and later removed from&#xD;
      the intervention (amendment protocol N-20200040 approved by the Ethics Committee of Northern&#xD;
      Jutland on February 2nd 2021).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 8, 2020</start_date>
  <completion_date type="Actual">April 28, 2021</completion_date>
  <primary_completion_date type="Actual">April 28, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Total equipotent dose of opioids</measure>
    <time_frame>24 hours</time_frame>
    <description>Sum of equipotent opioid doses during the first 24 hours after surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to first administration of opioids after surgery</measure>
    <time_frame>48 hours</time_frame>
    <description>In hours and minuts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numerical rating scale score</measure>
    <time_frame>24 hours</time_frame>
    <description>Pain score reported by the patient after surgery from 0 (no pain) to 10 (worst imaginable pain) in whole numbers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time for full mobilization</measure>
    <time_frame>Through study completion, an average of 1 week</time_frame>
    <description>The total time for full mobilization (walk with support)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total dose of non-opioid analgesics</measure>
    <time_frame>24 hours</time_frame>
    <description>Sum of non-opioid doses during the first 24 hours after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The need for pain medication at discharge</measure>
    <time_frame>At discharge from hospital, an average of 1 week</time_frame>
    <description>The need for pain medication at discharge (all forms, type, dose)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative complication (Empyema)</measure>
    <time_frame>At discharge from hospital, an average of 1 week</time_frame>
    <description>Empyema (yes/no) as complication to the surgery described in the patients journal at discharge (epicrisis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative complication (Air leakage)</measure>
    <time_frame>At discharge from hospital, an average of 1 week</time_frame>
    <description>Air leakage (yes/no) as complication to the surgery described in the patients journal at discharge (epicrisis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative complication (Reoperation)</measure>
    <time_frame>At discharge from hospital, an average of 1 week</time_frame>
    <description>Reoperation (yes/no) as complication to the surgery described in the patients journal at discharge (epicrisis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative complication (Pneumonia)</measure>
    <time_frame>At discharge from hospital, an average of 1 week</time_frame>
    <description>Pneumonia (yes/no) as complication to the surgery described in the patients journal at discharge (epicrisis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative complication (Drainage of pleural effusion)</measure>
    <time_frame>At discharge from hospital, an average of 1 week</time_frame>
    <description>Pleural effusion (yes/no) as complication to the surgery described in the patients journal at discharge (epicrisis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative complication (Oyxgen therapy)</measure>
    <time_frame>At discharge from hospital, an average of 1 week</time_frame>
    <description>The need for supplemental oxygen therapy and need for mechanical ventilation (yes/no) as complication to the surgery described in the patients journal at discharge (epicrisis)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">45</enrollment>
  <condition>Postoperative Pain</condition>
  <condition>Lung Cancer</condition>
  <condition>Video Assisted Thoracoscopic Surgery</condition>
  <condition>Thoracoscopic Surgery</condition>
  <condition>Nerve Block</condition>
  <condition>Local Anesthesia</condition>
  <arm_group>
    <arm_group_label>Before implementation</arm_group_label>
    <description>Perineural bupivacaine without adjuvants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>After implementation</arm_group_label>
    <description>Perineural bupivacaine with intravenous dexamethasone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Intravenous dexamethasone 8 mg. Given once at the end of surgery.</description>
    <arm_group_label>After implementation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacain</intervention_name>
    <description>Bupivacaine dose according to weight. &lt;60 kg: Total dose 100mg 60-90kg: Total dose 150mg &gt;90kg: Total dose 200mg&#xD;
Given once at the end of surgery.</description>
    <arm_group_label>Before implementation</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult lung cancer patients scheduled to undergo VATS at Aalborg University Hospital.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        ° Consecutive adult patients over 18 years of age scheduled to undergo VATS because of&#xD;
        verified/suspected lung cancer.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to understand verbal and written information.&#xD;
&#xD;
          -  Preexisting chronic pain condition.&#xD;
&#xD;
          -  Preoperative daily treatment with pain medication (Non-opioids, opioids,&#xD;
             gabapentin/pregabalin).&#xD;
&#xD;
          -  Previous thoracic surgery.&#xD;
&#xD;
          -  Previous chemotherapy due to thoracic malignancy and / or radiation therapy. to the&#xD;
             thorax.&#xD;
&#xD;
          -  Pregnant women.&#xD;
&#xD;
          -  Autoimmune neuromuscular diseases (sclerosis, peripheral neuromuscular disorders).&#xD;
             General muscle weakness or atrophy.&#xD;
&#xD;
          -  Hypersensitivity, allergy or intolerance to dexamethasone, bupivacaine or adrenaline.&#xD;
&#xD;
          -  Preoperative epidural anaesthesia.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jannie Bisgaard Stæhr, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Anaesthesia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <state>Region Of Northern Jutland</state>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>November 3, 2020</study_first_submitted>
  <study_first_submitted_qc>November 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2020</study_first_posted>
  <last_update_submitted>June 28, 2021</last_update_submitted>
  <last_update_submitted_qc>June 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Aalborg University Hospital</investigator_affiliation>
    <investigator_full_name>Jannie Bisgaard Stæhr</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

